Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients
IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and is poised for future drug approvals. This advanced testing protocol aims to provide deeper insights into the molecular characteristics of NSQ NSCLC, facilitating more personalized and effective treatment strategies.
Approximately 50% of NSQ NSCLCs lack a targetable gene driver mutation, making MET protein expression an important additional personalized target. Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in cell proliferation, invasion, and survival, making it a vital biomarker for targeted therapies.
"To our knowledge, Caris is the only lab in the US that has historically and is currently offering the MET (SP44) RxDx assay for NSQ NSCLC," said Caris President David Spetzler, MS, PhD, MBA. "With MET IHC testing already in place, we are poised and ready to provide a detailed molecular profile to inform targeted therapies and future drug development approvals."
Key Highlights of MET IHC Testing:Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors.
Identification of Actionable Targets: The MET IHC testing helps identify overexpression of the MET protein, which is associated with poor prognosis and can be targeted by specific therapies.
Enhanced Treatment Personalization: By understanding the molecular makeup of NSQ NSCLC tumors, oncologists can tailor treatment plans to the individual needs of patients, potentially improving outcomes and quality of life.
Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific research. Deployment of MET IHC testing for NSQ NSCLC patients underscores this commitment and highlights Caris' dedication to improving patient care and outcomes.
Caris' comprehensive molecular profile testing includes MI Cancer Seek® and Caris Assure®. Caris received FDA approval in November of 2024 for MI Cancer Seek®, a tissue-based assay which is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Caris Assure® is a powerful blood-based assay that uniquely identifies somatic tumor, incidental clonal hematopoiesis and incidental germline variants by sequencing both plasma and buffy coat through a WTS and WES-based assay.
About Caris Life SciencesCaris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.
Caris Life Sciences Media: Corporate CommunicationsCorpComm@CarisLS.com214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-provides-met-immunohistochemistry-testing-as-standard-of-care-for-non-squamous-non-small-cell-lung-cancer-patients-302451928.html
SOURCE Caris Life Sciences
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.
Yahoo
an hour ago
- Yahoo
International Oncology Experts Meet in Kenya to Address Regional Cancer Needs
National Comprehensive Cancer Network and African Cancer Coalition take part in American Cancer Society Global Academy Regional Workshop to improve cancer care in Sub-Saharan Africa. NAIROBI, Kenya, June 10, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is joining the African Cancer Coalition (ACC) to update cancer treatment recommendations during the American Cancer Society (ACS) 2025 Global Academy Regional Workshop: Sub-Saharan Africa, in Nairobi, Kenya, June 9-11. The ACS Global Academy Regional Workshop brings together oncology specialists from around the world to improve treatment and support for people with cancer. The three-day workshop includes two days devoted to updating NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) adapted specifically for the Sub-Saharan Africa region. Additional workshops will focus on improving utilization of those guidelines, navigation programs, and provider tools. "The ACS Global Academy Regional Meetings aim to provide a productive and dedicated space for providers to learn from one another, engage in discourse, and reach consensus on regional needs," said Anu Agrawal, MD, Vice President, Global Cancer Support, American Cancer Society. "Continuing the collaboration with ACC and NCCN on the development and update of NCCN Harmonized Guidelines™ provides an essential framework to better understand localized needs and priorities, a key part of this regional meeting in Nairobi." NCCN Guidelines® contain the latest evidence-based, expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care. They are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. Approximately half of the two million registered users are from outside the United States, across 190 different countries. The NCCN Global Program oversees adapting and translating the original recommendations to be more accessible for care providers worldwide. During the meeting, the following NCCN Harmonized Guidelines™ for Sub-Saharan will be updated: Anal Carcinoma Biliary Tract Cancers Bladder Cancer Cervical Cancer Colon Cancer Colorectal Cancer Screening Gestational Trophoblastic Neoplasia (GTN) Hepatocellular Carcinoma Kidney Cancer Ovarian Cancer Penile Cancer Rectal Cancer Testicular Cancer Uterine Neoplasms Vulvar Cancer "We have been working in collaboration with experts from ACC across the Sub-Saharan Africa area and ACS for many years to share guidelines that are both aspirational and pragmatic," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "In that time, we have seen improved capacity in cancer-related resources and care, but we have also seen increased cancer rates for the people who live in this region. Our commitment to collaborate with leading experts in the region to maintain and update treatment recommendations, based on the latest research and local circumstances, is more important than ever." Dr. Denlinger is representing NCCN at the meeting, along with Nadeem R. Abu-Rustum, MD, Memorial Sloan Kettering Cancer Center, Chair, NCCN Guidelines Panel for Cervical/Uterine Cancers; Al Benson, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chair, NCCN Guidelines Panels for Colon/Rectal/Anal Cancers and Hepatobiliary Cancers; Thomas Flaig, MD, University of Colorado Cancer Center, Chair, NCCN Guidelines Panel for Bladder/Penile Cancers; Lisa Gurski, PhD, Manager, Licensed Clinical Content, NCCN; Vaishnavi Sambandam, PhD, Oncology Scientist/Medical Writer, NCCN; and Katy Winckworth-Prejsnar, MPH, Director, Global Program, NCCN. Visit to learn more about free resources for improving cancer treatment around the world. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact: Rachel Darwin267-622-6624darwin@ View original content to download multimedia: SOURCE National Comprehensive Cancer Network Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Business Wire
an hour ago
- Business Wire
Spineology ® Announces the Launch of OptiMesh Align™
ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology Inc., the pioneers of Conform and Expand™ Technology, today announced the launch of its latest innovation, and most advanced patient specific solution yet: OptiMesh Align™ (Align). Built on the proven foundation of OptiMesh ®, Align is uniquely engineered to provide real time, in-situ, independent anterior and posterior implant expansion resulting in a customized, patient specific lordotic shape up to 20 degrees. Align is delivered through one of the smallest insertion profiles available, expanding to one of the largest implant footprints, enabling correction not typically associated with minimally invasive posterior spine approaches. OptiMesh utilizes a biologics-based expansion method, which is designed to overcome limitations and reduce point-loading commonly seen with mechanically expandable implant technology. 'Sagittal alignment is widely considered one of the key correlative indicators to achieving long term clinical success for spine patients. The OptiMesh technology remains the only conforming expandable implant that offers a personalized solution for each patient,' said Brian Snider, Chief Executive Officer. 'With the addition of the lordotic capabilities of the Align implant, our portfolio provides more options to achieve the clinical requirements of surgery.' OptiMesh Align is engineered to produce distraction forces and endplate conformance, provide strength and stability to restore disc height, create a robust fusion scaffold, and now further supports the achievement of alignment objectives. This breakthrough is driven by Spineology's proprietary Conform and Expand flexible mesh interbody technology, setting a new standard for patient specific lumbar interbody fusion. About Spineology Spineology Inc. are the pioneers of Conform and Expand™ technology, a novel development method used in the design of spinal expandable implants. Spineology's core portfolio, OptiMesh ® is the only conforming patient specific spinal implant on the market. OptiMesh is backed with IDE level data which further sets the company apart from traditional fusion procedures. OptiMesh is designed to enable surgeons to support outcomes, and patient recovery while minimizing tissue disruption. With a strong commitment to patient-centered care, Spineology aspires to provide every spine patient the freedom from pain through the creation and delivery of ultra-MIS solutions. For more information about Spineology, visit and follow us on LinkedIn, or Twitter.
